Skip to search formSkip to main contentSkip to account menu

epratuzumab/rituximab

Known as: MOAB IDEC-C2B8/MOAB LL2 
National Institutes of Health

Related topics

Related topics

2 relations
epratuzumabrituximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long…
Background The safety and efficacy of epratuzumab, a monoclonal antibody targeting CD22, were assessed in EMBLEM™, a 12-week… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)